Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) is expected to release its earnings data on Thursday, February 6th. Analysts expect Rapport Therapeutics to post earnings of ($0.62) per share for the quarter.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.07. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Rapport Therapeutics Stock Up 1.2 %
Shares of RAPP opened at $16.60 on Tuesday. Rapport Therapeutics has a 1-year low of $12.09 and a 1-year high of $29.74. The firm’s 50-day moving average price is $17.78 and its 200-day moving average price is $20.45.
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- What Are the U.K. Market Holidays? How to Invest and Trade
- How to Invest in Small Cap Stocks
- Investing In Automotive Stocks
- These Are the Dividend Stocks Insiders Bought in January
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
